Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27831775 | 0.90 | ALDH1A1 (0.43) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL3230387 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL7608822 | 0.79 | ALDH1A1 (0.37) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL15712632 | 0.77 | ALDH1A1 (0.39) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL3463298 | 0.76 | EPHX1 (0.41) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| Cyclohexane SCHEMBL8927660 | 0.75 | ALDH1A1 (0.59) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL27797780 | 0.73 | ALDH1A1 (0.40) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL9750853 | 0.73 | — | — | |
| SCHEMBL31289958 | 0.73 | ALDH1A1 (0.33) | ALDH1A1CHRM5CHRM1CHRM3LMNA | |
| SCHEMBL16404744 | 0.72 | ALDH1A1 (0.39) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105051051-B | Method for synthesizing sphingomyelin and dihydrosphingomyelin | 萨瑞斯治疗控股公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3842443-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | Cerenis Therapeutics Holding SA (FR) | 2021-06-30 | — | — | EP | disclosed |
| EP-3363805-B1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2020-12-16 | — | — | EP | disclosed |
| EP-3363805-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | Cerenis Therapeutics Holding SA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-20170204122-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-20 | — | — | US | disclosed |
| US-9708354-B2 | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-18 | — | — | US | disclosed |
| US-9643915-B2 | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-05-09 | — | — | US | disclosed |
| US-20160075634-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-03-17 | — | — | US | disclosed |
| EP-2970344-A2 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | Cerenis Therapeutics Holding SA (FR) | 2016-01-20 | — | — | EP | disclosed |
| CN-105051051-A | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins | CERENIS THERAPEUTICS HOLDING S A | 2015-11-11 | — | — | CN | disclosed |
| WO-2014140787-A2 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275590-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2014-09-18 | — | — | US | disclosed |
| US-6291433-B1 | Derivatives of α-D-Thioxyloside and their use against atheroma | FOURNIER INDUSTRIE ET SANTE (FR) | 2001-09-18 | — | — | US | disclosed |
| CN-1305486-A | Novel compounds derived from alpha-D-xylose, preparation method and therapeutic use | FOURNIER IND & SANTE (FR) | 2001-07-25 | — | — | CN | disclosed |
| US-H327-H | Nematicidal alkenanilides | FMC CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075634-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | ALDH1A1 2913/4885CHRM5 3622/4885CHRM1 4286/4885 |
| US-20140275590-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | ALDH1A1 2913/4885CHRM5 3622/4885CHRM1 4286/4885 |
| US-20170204122-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | ALDH1A1 2913/4885CHRM5 3622/4885CHRM1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.